vimarsana.com
Home
Live Updates
Gammagard Liquid Approved for Chronic Inflammatory Demyelina
Gammagard Liquid Approved for Chronic Inflammatory Demyelina
Gammagard Liquid Approved for Chronic Inflammatory Demyelinating Polyneuropathy
The approval was based on data from the phase 3 ADVANCE-CIDP 2 study, which included 18 adults with CIDP who developed a relapse in the ADVANCE-CIDP 1 study after receiving treatment with HyQvia.
Related Keywords
,
Drug Administration ,
Gammagard Liquid ,
Inflammatory Neuropathy Cause ,
Rasch Built Overall Disability Scale ,